Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Zavicefta® is indicated for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)1
Zinforo® is indicated for the treatment of community-acquired pneumonia (CAP) in neonates, infants, children, adolescents and adults2
When there’s no time to wait, evidence supports the use of Zinforo® in your CAP patients:
The efficacy and safety profile of Zavicefta® make it a much-needed option for physicians faced with the challenge of treating hospitalised patients with HAP/VAP caused by suspected or confirmed resistant, aerobic Gram-negative bacteria, where the consequences of antibiotic failure can be devastating1,9,11,12
**Zavicefta is indicated for treatment of complicated urinary tract infections, including pyelonephritis; complicated intra-abdominal infections; and hospital-acquired pneumonia, including ventilator-associated pneumonia infections in adults and paediatric patients aged 3 months and older.
Zavicefta is also indicated for the treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.1
†Zinforo® is indicated for the treatment of patients with complicated skin and soft tissue infections and community-acquired pneumonia.2
‡Applies only for standard dose regimens in adults and children from 2 months of age, including patients with renal impairment. For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis). Infusion times of <60 minutes are based on PK/PD analyses only.1
βDosage adjustment required for patients with moderate or severe renal impairment (CrCl ≤50 mL/min).1
Zavicefta® (ceftazidime and avibactam) and Zinforo® (ceftaroline fosamil)
for the treatment of community-acquired pneumonia (CAP) in neonates, infants, children, adolescents and adults2
for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)1
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
OK, We will need you to sign in before we can determine if you are aligned with a Pﬁzer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?